Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

12.41 -0.72

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.97

Massimo

12.65

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

125.6

57.371

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+15.68% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

271M

2.2B

Apertura precedente

13.13

Chiusura precedente

12.41

Notizie sul Sentiment di mercato

By Acuity

100%

0%

329 / 340 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 ago 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

18 ago 2026, 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

18 ago 2026, 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

18 ago 2026, 23:51 UTC

News
Social Media
Event

La-Z-Boy Inc reported a net loss of $2.29 million and lowered its revenue guidance, leading shares to trade lower in after-market hours.

18 ago 2026, 23:51 UTC

News

JBS N.V. has proposed to acquire an 18% stake in Pilgrim's Pride, offering 2.086 shares per Pilgrim's Pride share. Shares are higher in after-market trading.

18 ago 2026, 23:46 UTC

News

Blue Owl Capital shares are lower in after-market hours following a recent bond issuance of $400 million by its affiliate. Analysts estimate fair value at $12.38.

18 ago 2026, 23:41 UTC

News
Social Media

UGI Corp shares rose in after-market trading on news of KKR's unsolicited $9 billion acquisition proposal, valuing the company at about $42.50 per share.

18 ago 2026, 23:41 UTC

News

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

18 ago 2026, 23:36 UTC

News

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

18 ago 2026, 23:36 UTC

News
Correlated Moves

SPDR Gold Shares trade lower in after-market hours as Indonesia holds rates steady, while rising crude oil prices may affect inflation and market dynamics.

18 ago 2026, 23:21 UTC

News
Correlated Moves

Silver is trading lower in after-market hours, reflecting a decline alongside the United States Copper Index Fund. Silver remains above its 20-day moving average.

18 ago 2026, 23:21 UTC

Event
News

Jack Henry & Associates projects fiscal 2027 GAAP sales of $2.684 billion to $2.709 billion, exceeding analyst estimates, as shares rise in after-market hours.

18 ago 2026, 23:21 UTC

News

Evolution Petroleum shares are lower in after-market trading following a public offering announcement to fund a $16 million acquisition in the Midland Basin.

18 ago 2026, 23:21 UTC

News

Norfolk Southern completed its Living Shoreline project and advanced in after-market trading, showing strength above its 20-day moving average.

18 ago 2026, 23:21 UTC

News

Enovix Corporation shares rise in after-market hours as executives reassure investors and reaffirm Q3 2026 revenue guidance of $9.0 million to $10.0 million.

18 ago 2026, 23:11 UTC

Correlated Moves
News

Photronics Inc is facing a potential securities fraud lawsuit, contributing to a decline in after-market trading. The Russell 2000 Index also showed a slight decrease.

18 ago 2026, 23:06 UTC

News
Social Media

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

18 ago 2026, 23:02 UTC

News
Correlated Moves
Social Media

Price target raised to $1,250; shares lower in after-market.

18 ago 2026, 23:01 UTC

News

Toll Brothers reported third-quarter earnings of $280.1 million, exceeding expectations. Shares are trading higher in after-market hours following the results.

18 ago 2026, 23:01 UTC

News

Automatic Data Processing shares are lower in after-market trading despite a rebound in U.S. private-sector hiring, amid rising U.S. Treasury yields.

18 ago 2026, 23:01 UTC

News
Social Media

Mercury Systems shares fell after reporting a decline in net income to $798,000 and missing adjusted EPS estimates by $0.02 in after-market trading.

18 ago 2026, 23:01 UTC

News

Union Pacific shares are higher in after-hours trading as the Surface Transportation Board advances merger discussions with Norfolk Southern, boosting investor sentiment.

18 ago 2026, 23:01 UTC

News
ETF Constituents

The Vanguard Growth ETF is higher in after-market trading, supported by gains in META and AMZN, despite broader market pressures from inflation and geopolitical tensions.

18 ago 2026, 23:01 UTC

News
Social Media
Event

Keysight Technologies reported third-quarter revenue of $1.846 billion, exceeding expectations. Shares rose in after-market trading following the strong earnings and raised guidance.

18 ago 2026, 23:01 UTC

News

Blue Owl Capital shares are higher in after-market hours as Blue Owl Technology Finance prices $400 million in bonds, exceeding its $200 million target.

18 ago 2026, 23:01 UTC

News
Social Media

Dell Technologies shares are lower in after-market trading amid broader market pressures and rising U.S. Treasury yields ahead of its September 1 earnings call.

18 ago 2026, 23:01 UTC

News

Kennametal Inc appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, prompting shares to advance in after-market trading.

18 ago 2026, 22:02 UTC

News

Curtiss-Wright Corp announced a $100 million expansion of its share repurchase program, raising total buybacks to $260 million for 2026. Shares are higher in after-market trading.

18 ago 2026, 21:03 UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

18 ago 2026, 21:01 UTC

News

Cinemark Holdings Inc. shares rise after *Spider-Man: Brand New Day* becomes the highest-grossing domestic film in the company's history within three weeks of release.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

15.68% in crescita

Previsioni per 12 mesi

Media 14.53 USD  15.68%

Alto 16 USD

Basso 13.6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

1

Acquista

2

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat